Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MPO | P05164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14188805 | 0.90 | KDM4E (0.41) | KDM4ELMNAPKMADORA1ADORA3 | |
| SCHEMBL14188810 | 0.84 | NPC1 (0.45) | KDM4ELMNAPKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL14188813 | 0.84 | TSHR (0.40) | KDM4ELMNAPKMADORA1ADORA3 | |
| SCHEMBL12713296 | 0.83 | KDM4E (0.49) | KDM4ELMNAPKMADORA1ADORA3 | |
| SCHEMBL203832 | 0.81 | KDM4E (0.48) | KDM4ELMNAPKMADORA1ADORA3 | |
| SCHEMBL201295 | 0.81 | LMNA (0.51) | KDM4ELMNAPKMADORA1ADORA3 | |
| SCHEMBL3507658 | 0.81 | KDM4E (0.51) | KDM4ELMNAPKMADORA1ADORA3 | |
| SCHEMBL12509518 | 0.80 | KDM4E (0.47) | KDM4ELMNAPKMADORA1ADORA3 | |
| SCHEMBL12024804 | 0.80 | KDM4E (0.47) | KDM4ELMNAPKMADORA1ADORA3 | |
| SCHEMBL416916 | 0.80 | KDM4E (0.61) | KDM4ELMNAPKMADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737809-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-1737809-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7816367-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816367-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816367-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7649110-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649110-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649110-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1737809-A4 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1737809-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| CN-1141300-C | Acrylonitrile compounds | �ղ���ѧ��ҵ��ʽ���� | 2004-03-10 | — | — | CN | disclosed |
| US-6642234-B1 | Insecticides, acaricides, nematocides, herbicides and fungicides, | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1142882-A9 | ACRYLONITRILE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2002-10-02 | — | — | EP | disclosed |
| CN-1333759-A | Acrylonitrile compounds | NISSAN CHEMICAL IND LTD (JP) | 2002-01-30 | — | — | CN | disclosed |
| EP-1142882-A1 | ACRYLONITRILE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | KDM4E 4456/4885LMNA 411/4885PKM 214/4885 |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | KDM4E 4456/4885LMNA 411/4885PKM 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.